Journal
CLINICAL OBSTETRICS AND GYNECOLOGY
Volume 52, Issue 3, Pages 469-482Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/GRF.0b013e3181b52e20
Keywords
depression; pregnancy; antidepressants; safety; PPHN; neonatal withdrawal syndrome
Categories
Funding
- NIH
- Foundation of Hope
- Astra Zeneca
- GlaxoSmithKline
- Stanley Medical Research Institute
- Novartis Pharmaceuticals
- Repligen Corporation
Ask authors/readers for more resources
The treatment of depression during pregnancy is both a common and complex clinical challenge. The decision to expose the fetus to antidepressant medication during pregnancy must be weighed against the risks of untreated maternal depression to both mother and fetus. Maternal depression during pregnancy has been associated with increased rates of preterm birth and maternal substance use. The safety of antidepressant use during pregnancy seems to be largely reassuring but there remain 2 areas of controversy including neonatal withdrawal syndrome and primary pulmonary hypertension of the newborn. Individualized treatment recommendations based on the patient's history are essential to optimize outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available